Literature DB >> 12916800

Human deficiencies in type-1 cytokine receptors reveal the essential role of type-1 cytokines in immunity to intracellular bacteria.

Tom H M Ottenhoff1, Tjitske De Boer, Jaap T van Dissel, Frank A W Verreck.   

Abstract

Human genetic factors play an important role in determining the outcome of infections caused by intracellular pathogens, including mycobacteria and salmonellae (reviewed in 1). The genetic elements involved and the mechanisms by which these control disease-susceptibility versus resistance, however, remain incompletely characterized. Recent studies on patients with idiopathic, severe infections due to poorly pathogenic mycobacteria and salmonellae have revealed that many of these patients are unable to produce or respond to IFN-gamma. This inability results from causative, deleterious genetic mutations in either one of five different genes in the type-1 cytokine cascade, encoding IL-12p40, IL-12Rbeta1, IFN-gammaR1, IFN-gammaR2 or Stat-1. The mutational events can lead to complete or partial deficiency, and are mostly autosomal recessive but can be dominant negative as well. The immunological, clinical and histopathological phenotypes resulting from the ten groups of genetic type-1 cytokine (receptor) deficiency distinguished thus far differ significantly. These findings are summarized, discussed and placed in a broader context in relation to protective immune mechanisms and disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12916800     DOI: 10.1007/978-1-4615-0059-9_24

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Dose-dependent immune response to Mycobacterium bovis BCG vaccination in neonates.

Authors:  Virginia Davids; Willem Hanekom; Sebastian J Gelderbloem; Anthony Hawkridge; Gregory Hussey; Ronel Sheperd; Lesley Workman; Jorge Soler; Rose Ann Murray; Stanley R Ress; Gilla Kaplan
Journal:  Clin Vaccine Immunol       Date:  2006-12-20

Review 2.  Role of innate host defenses in susceptibility to early-onset neonatal sepsis.

Authors:  James L Wynn; Ofer Levy
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

3.  Monitoring of peptide-specific and gamma interferon-productive T cells in patients with active and convalescent tuberculosis using an enzyme-linked immunosorbent spot assay.

Authors:  Fang-Fang Yang; Zhi-Quan Tu; Yi-Min Fang; Yan Li; Yi Peng; Tao Dong; Cong Wang; Shu-Xian Lin; Neng-Yong Zhan; Zhi-Ming Ma; Yong-Zhong Feng; Shou-Yong Tan; Xiao-Min Lai
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

4.  Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.

Authors:  Steven G Smith; Maeve K Lalor; Patricia Gorak-Stolinska; Rose Blitz; Natalie E R Beveridge; Andrew Worth; Helen McShane; Hazel M Dockrell
Journal:  BMC Immunol       Date:  2010-07-07       Impact factor: 3.615

5.  Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.

Authors:  Andreia P Soares; Thomas J Scriba; Sarah Joseph; Ryhor Harbacheuski; Rose Ann Murray; Sebastian J Gelderbloem; Anthony Hawkridge; Gregory D Hussey; Holden Maecker; Gilla Kaplan; Willem A Hanekom
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

6.  Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.

Authors:  Steven G Smith; Simone A Joosten; Virginie Verscheure; Ansar A Pathan; Helen McShane; Tom H M Ottenhoff; Hazel M Dockrell; Françoise Mascart
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

7.  Decreased expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4⁺ T cells and peripheral blood from tuberculosis patients.

Authors:  Katja Kleinsteuber; Kerrin Heesch; Stefanie Schattling; Malte Kohns; Claudia Sander-Jülch; Gerhard Walzl; Anneke Hesseling; Ertan Mayatepek; Bernhard Fleischer; Florian M Marx; Marc Jacobsen
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.